Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One Cycle in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy

Next Previous
Trial Profile

An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One Cycle in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Degarelix (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Ferring Pharmaceuticals

Most Recent Events

  • 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 26 Jun 2013 Planned end date changed from 1 Jun 2014 to 1 Jul 2013 as reported by ClinicalTrials.gov.
  • 20 Apr 2013 Planned number of patients changed from 200 to 220 as reported by European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top